Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
One of the constants in the 8 years since Lipitor lost market exclusivity has been that Humira (adalimumab) will top any biggest-selling drug chart (Table 1). Indeed, such is Humira’s supremacy that the anti-TNF monoclonal antibody is set to take Lipitor’s crown as the industry’s most successful drug, surpassing its cumulative sales this year. Much of this dominance has been not only through its success as a therapy for rheumatoid arthritis and other immune disorders, but also AbbVie’s efforts to defend the patents of the product that still makes up almost two-thirds of its sales. This has meant that despite the approval of five biosimilars in the USA, none has yet launched. However, with US biosimilar sales expected in 2023, Humira’s star is set to wane — albeit slowly.